← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

Stiff Person Syndrome

MONDO:0008491 Curated 2026-07-04T00:00:00Z 9 harmonized findings
falcon · 26 citations asta · 20 citations perplexity · 41 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

Stiff Person Syndrome is an antibody-mediated autoimmune disorder whose core lesion is failure of GABAergic inhibitory synaptic control in the CNS, producing continuous motor-unit activity, stiffness, and stimulus-triggered spasms.

UNANIMOUS INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 95% SPSD are antibody‑associated, immune‑mediated disorders characterized by failure of inhibitory synaptic control in the CNS, primarily involving GABAergic and (in PERM and subsets) glycinergic transmission.
Falcon frames SPS as an antibody-associated failure of inhibitory synaptic control involving GABAergic (and glycinergic) transmission.
DOI:10.1212/nxi.0000000000200109
perplexity CONCORDANT 95% The disease represents a paradigmatic example of antibody-mediated autoimmunity targeting inhibitory neurotransmission, specifically affecting the GABAergic system that normally provides critical inhibitory control of motor neuron firing.
Perplexity independently characterizes SPS as antibody-mediated autoimmunity against the GABAergic inhibitory system controlling motor neuron firing.
asta SILENT —
Asta is a retrieval-only run whose returned papers are all unrelated diseases (progeria, cardiomyopathy, ALS, LGMD, etc.); none address SPS pathophysiology.

GAD65 is the principal autoantigen; anti-GAD65 antibodies impair synthesis of GABA (the rate-limiting decarboxylation of glutamate), reducing inhibitory tone.

UNANIMOUS INTEGRATED
pathophysiologygenetic_factor
ProviderStanceScoreEvidence
falcon CONCORDANT 90% Anti‑GAD65 targets GAD65 at presynaptic terminals, diminishing activity‑dependent GABA synthesis
Falcon states anti-GAD65 targets presynaptic GAD65 and diminishes GABA synthesis, but gives only a qualitative frequency ("frequent anti-GAD65").
DOI:10.1212/nxi.0000000000200109
perplexity CONCORDANT 95% represents the most commonly targeted autoantigen in SPS, identified in 70 to 80 percent of classic SPS cases
Perplexity gives the quantitative frequency (70-80% of classic SPS) and the rate-limiting-enzyme mechanism, concordant with and more specific than Falcon.
PMID reference [1][9] in report
asta SILENT —
Asta returned no SPS-relevant papers and does not mention GAD65.

Intrathecal B-cell activation is evidenced by CSF oligoclonal IgG bands in ~67% and an elevated GAD65-specific IgG index in ~85% of patients, indicating clonal B-cell activity within the CNS compartment.

UNANIMOUS INTEGRATED
diagnosispathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 97% with oligoclonal bands in 67% and elevated GAD65‑specific IgG index in 85%
Falcon reports the identical CSF figures (OCB 67%, GAD65 IgG index 85%) as markers of intrathecal clonal B-cell activation.
DOI:10.1212/nxi.0000000000200109
perplexity CONCORDANT 97% Approximately 67 percent of patients demonstrate oligoclonal IgG bands in the CSF, and approximately 85 percent exhibit increased GAD65-specific IgG index values
Perplexity gives the same 67%/85% CSF statistics, an exact numerical match with Falcon (both trace to the Dalakas review).
PMID reference [5] in report
asta SILENT —
Asta returned no SPS CSF/serology data.

Impaired GABAergic inhibition manifests physiologically as reduced brain/CSF GABA (on MR spectroscopy) and loss of spinal reciprocal inhibition with cortical hyperexcitability, driving co-contraction of agonist and antagonist muscles.

UNANIMOUS INTEGRATED
pathophysiologyphenotype
ProviderStanceScoreEvidence
falcon CONCORDANT 85% Loss of reciprocal inhibition in spinal circuits and cortical hyperexcitability due to impaired GABAergic transmission
Falcon names loss of spinal reciprocal inhibition plus cortical hyperexcitability and elsewhere notes reduced brain/CSF GABA on MRS.
DOI:10.1212/nxi.0000000000200109
perplexity CONCORDANT 90% Magnetic resonance spectroscopy studies have revealed a prominent and highly significant decrease in GABA levels specifically in the sensorimotor cortex of SPS patients compared to controls, with the ratio of GABA to creatine reduced by 30 to 40 percent
Perplexity quantifies the MRS GABA reduction (30-40% in sensorimotor cortex) and details the reciprocal-inhibition/motor-cortex hyperexcitability mechanism.
PMID reference [4][30] in report
asta SILENT —
Asta returned no data on GABA levels or reciprocal inhibition.

Beyond GAD65, additional synaptic autoantigens define clinical subsets: GABARAP (~70% of sera), glycine receptor (GlyR, associated with PERM), amphiphysin (paraneoplastic), and gephyrin.

UNANIMOUS INTEGRATED
pathophysiologygenetic_factor
ProviderStanceScoreEvidence
falcon CONCORDANT 90% additional antibodies: GABARAP (~70%), GlyR (10–12%), amphiphysin (~5%), rare gephyrin
Falcon enumerates the same additional autoantibodies with frequencies (GABARAP ~70%, GlyR 10-12%, amphiphysin ~5%, rare gephyrin).
DOI:10.1212/nxi.0000000000200109
perplexity CONCORDANT 90% GABA receptor-associated protein (GABARAP) was identified as a novel autoantigen in approximately 70 percent of SPS patient sera compared with only 10 percent of controls
Perplexity gives GABARAP (~70%) plus dedicated sections on GlyR/PERM, amphiphysin (paraneoplastic), and gephyrin, concordant with Falcon.
PMID reference [1][3] in report
asta SILENT —
Asta returned no data on SPS autoantigens.

SPS spans a clinical spectrum: classic (axial) SPS, focal stiff-limb variant, SPS-plus with cerebellar/brainstem signs, and the severe PERM variant with myoclonus and autonomic dysfunction.

UNANIMOUS INTEGRATED
phenotype
ProviderStanceScoreEvidence
falcon CONCORDANT 90% SPS‑plus adds cerebellar/brainstem signs; PERM features brainstem/autonomic involvement and myoclonus
Falcon describes the classic/stiff-limb/SPS-plus/PERM spectrum, including cerebellar-brainstem SPS-plus and myoclonic/autonomic PERM.
DOI:10.1007/s00415-023-12123-0
perplexity CONCORDANT 90% PERM represents a more severe and rapidly progressive variant of SPS characterized by rigidity of both axial and limb muscles combined with diffuse myoclonus and prominent autonomic dysfunction
Perplexity covers classic SPS, partial variants (stiff-limb, stiff-trunk, cerebellar), and PERM, concordant with Falcon's spectrum.
PMID reference [1][13][50] in report
asta SILENT —
Asta returned no SPS phenotype/variant descriptions.

SPS is rare (roughly one per million / ~0.11 per 100,000) with a female predominance and typical adult onset.

MAJORITY LEAD
epidemiology
ProviderStanceScoreEvidence
falcon CONCORDANT 85% 76% female; median onset 51 years (Japan); SPSD cohort mean onset 42.9 years, 75.8% female
Falcon provides prevalence (0.11/100,000, Japan), a ~76% female predominance, and adult median onset figures.
DOI:10.1212/nxi.0000000000200165, DOI:10.1007/s00415-023-12123-0
perplexity PARTIAL 50% with an estimated prevalence of approximately one in one million individuals
Perplexity gives a concordant prevalence (~1 per million) but does not report an overall sex ratio or age of onset, so it only partly covers the finding.
PMID reference [1][8] in report
asta SILENT —
Asta returned no SPS epidemiology.

Management is two-pronged: GABA-enhancing symptomatic drugs (benzodiazepines, baclofen) plus immunotherapy, with IVIg as the preferred first-line immunotherapy and rituximab / B-cell depletion for refractory disease.

UNANIMOUS INTEGRATED
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 90% Symptomatic GABA‑enhancing therapy: benzodiazepines (GABA‑A PAMs), baclofen (GABA‑B agonist), tizanidine, gabapentin
Falcon describes the GABA-enhancing symptomatic tier and elsewhere IVIg as first-line immunotherapy (~75%) with rituximab for refractory cases.
DOI:10.7759/cureus.67887, DOI:10.1007/s00415-025-13157-2
perplexity CONCORDANT 90% Intravenous immunoglobulin (IVIG) represents the most effective immunotherapy for SPS, demonstrating the most robust evidence of clinical benefit
Perplexity names benzodiazepines/baclofen as symptomatic first-line and IVIG as the most effective immunotherapy, with rituximab for non-responders.
PMID reference [1][5][9][20] in report
asta SILENT —
Asta returned no SPS treatment data.

Genetic predisposition extends beyond the classic HLA class II associations to novel immune-related loci, notably KLK10 variants reported in ~95% of SPS patients (with ORAI1 and LILRA4 also implicated).

MAJORITY LEAD
genetic_factor
ProviderStanceScoreEvidence
perplexity CONCORDANT 90% Whole-exome sequencing of GAD-positive SPS patients revealed consistent polymorphisms in the KLK10 gene, identified in 95 percent of individuals with SPS but absent in controls and GAD-positive individuals without neurologic symptoms
Perplexity uniquely reports the KLK10 whole-exome finding (95%) plus ORAI1 and LILRA4, alongside the HLA DQB1*0201 association.
PMID reference [6][15] in report
falcon PARTIAL 30% Genetic/immune predisposition (HLA class II associations reported)
Falcon notes only the HLA class II predisposition and is silent on KLK10 and the other novel loci, so it supports only the general genetic-predisposition claim.
DOI:10.7759/cureus.67887
asta SILENT —
Asta returned no SPS genetics.

Narrative

Overview

All three reports were commissioned on the same autoimmune-pathophysiology template, but only two returned usable coverage. Falcon (Edison, SPS-focused, 26 citations) and perplexity (sonar-deep-research, comprehensive, 41 citations) both frame Stiff Person Syndrome as an antibody-mediated failure of GABAergic inhibitory neurotransmission in the CNS, with high-titer anti-GAD65 antibodies as the central biomarker, impaired GABA synthesis and loss of reciprocal inhibition as the physiologic lesion, and a two-pronged treatment logic (GABA-enhancing symptomatic drugs plus immunotherapy). Perplexity reads as an exhaustive narrative review; falcon reads as a tightly cited mechanistic brief anchored on the Dalakas 2023 therapy review and recent cohort studies. Asta was a retrieval-only run and returned no on-topic material.

Agreement

Falcon and perplexity converge strongly and without contradiction on the core disease model: antibody-associated impairment of GABAergic (and, in PERM, glycinergic) inhibition; GAD65 as the principal autoantigen; a spectrum of additional synaptic autoantigens (GABARAP ~70%, GlyR/PERM, amphiphysin in paraneoplastic disease, gephyrin); the clinical spectrum of classic SPS, stiff-limb, SPS-plus, and PERM; and a symptomatic-plus-immunotherapy treatment frame with IVIg first-line and rituximab for refractory disease. Most strikingly, both cite the identical CSF statistics for intrathecal B-cell activation (oligoclonal bands in 67%, elevated GAD65-specific IgG index in 85%), which trace back to the same Dalakas source.

Divergence

Divergence is one of coverage and granularity rather than genuine conflict. Perplexity contributes unique depth and leads: quantitative MR-spectroscopy data (30-40% GABA reduction in sensorimotor cortex), motor-cortex hyperexcitability by TMS, and novel genetic markers beyond HLA (KLK10 in ~95% of patients, plus ORAI1 and LILRA4), as well as emerging therapies (anti-CD19 CAR T-cells, extracorporeal photopheresis). Falcon contributes cohort epidemiology (0.11/100,000 in Japan, ~76% female, adult onset), prognostic signal (early immunotherapy improves outcomes; brainstem/cerebellar involvement predicts worse outcome), and complement inhibition (eculizumab) in GlyR-antibody-positive disease. Asta contributed no on-topic coverage whatsoever: its retrieval returned only unrelated diseases (progeria, cardiomyopathy, liver fibrosis, ALS, LGMD, Parkinson's, mitochondrial disease), so it is silent across every harmonized finding and adds nothing to the synthesis.

Integration

The falcon/perplexity consensus is solid enough to promote as curated content: the antibody-mediated GABAergic mechanism, GAD65 as principal antigen with impaired GABA synthesis, intrathecal B-cell activation (OCB 67% / IgG index 85%), reduced brain/CSF GABA with loss of reciprocal inhibition and cortical hyperexcitability, the additional-autoantigen subsets, the classic/stiff-limb/ SPS-plus/PERM spectrum, and the GABA-enhancing-plus-IVIg/rituximab treatment frame. Each of these is dual-sourced and internally consistent with the existing disorder YAML.

Not integrated (leads)

Two findings are retained as leads rather than promoted. The epidemiology claim is single-provider-strong (falcon's cohort figures) with only partial perplexity corroboration (prevalence but no sex ratio/onset), so the precise numbers should be verified against primary sources before promotion. The novel-genetics finding (KLK10 ~95%, ORAI1, LILRA4) is reported only by perplexity and rests on a single whole-exome study; it is a promising but unconfirmed lead that needs independent replication before it enters the disorder YAML. Perplexity's CAR-T and photopheresis material is likewise emerging and left as a lead.

Three providers were compared: falcon (Edison, SPS-focused pathophysiology, 26 citations) and perplexity (sonar-deep-research, comprehensive 41-citation report) are both on-topic and broadly concordant, agreeing on the antibody-mediated GABAergic mechanism, GAD65 as principal antigen, intrathecal B-cell activation (OCB 67% / IgG index 85%, an exact numerical match), the additional-autoantigen subsets, the clinical spectrum, and the symptomatic-plus-immunotherapy treatment frame. Divergence is coverage/granularity rather than conflict: perplexity adds quantitative detail (MRS GABA 30-40% reduction) and unique leads (KLK10/ORAI1/LILRA4 genetics, CAR-T and extracorporeal photopheresis), while falcon adds cohort epidemiology (0.11/100,000, ~76% female) and complement inhibition (eculizumab) in GlyR-positive disease. No CONTRADICTORY stances were found. The asta report is a retrieval-only run that returned exclusively off-topic papers (progeria, cardiomyopathy, liver fibrosis, ALS, LGMD, Parkinson's, mitochondrial disease); it contributes no SPS-relevant content and is therefore SILENT on every finding. best_matching_text values are verbatim excerpts from the report files; literature citations here are provider-reported and left unverified pending fetch-reference checks.